Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Testosterone therapy linked to CV risk in men with HIV

Publish date:: March 10, 2020

Key clinical point: Men with HIV are likely prone to the same cardiovascular risks from testosterone therapy as other men.

Major finding: The risk of significant coronary artery calcium progression was 2.0 times greater among continuous users and 2.4 times greater among new users, compared with former users.

Study details: A review of 300 men who have sex with men

Disclosures: The work was funded by the National Institutes of Health. The lead investigator didn't report any disclosures.

Citation:

Haberlen S et al. CROI 2020, Abstract 662.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Infectious Diseases

Obesity, hypoxia predict severity in children with COVID-19,

Prophylactic HIV treatment in female STI patients is rare,

Combo DAA treatments may benefit patients with resistant HCV genotype 3,

Pronounced racial differences in HBsAg loss after stopping nucleos(t)ide,

Opt-out policy at a syringe service program increased HIV/HCV testing,